$TAK

Greenway Nicola Deidre Petal sold $116K of TAK

Greenway Nicola Deidre Petal (Chief Human Resources Officer) sold 6,774 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.12M total) on 2026-08-10.

Original reporting
SEC EDGAR · Greenway Nicola Deidre Petal
Published Aug 13, 2026, 1:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the CHRO’s open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; the filing provides no motive or forward-looking information.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

This is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda disclosed an insider open-market sale by its CHRO, Greenway Nicola Deidre Petal, of 6,774 shares at $17.10.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and small versus normal insider activity.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but no accompanying company guidance, operational update, or regulatory/legal catalyst.

Market effects

Insider selling in a large pharma name is not a sector-level signal without additional context.

None indicated; the disclosure is company-specific.

None indicated; no cross-border deal, trial, or regulatory action is described.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted as less “scheduled,” but the disclosed sale size is still modest relative to typical institutional flows.

Key entities

  • Takeda Pharmaceutical Co Ltd

    Subject of the Form 4 insider transaction disclosure.

  • Greenway Nicola Deidre Petal

    Chief Human Resources Officer who sold 6,774 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.